Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|January 2, 2005
- Pharmaceutical Technology-01-02-2005
- Volume 29
- Issue 1
The Outsourcing Advantages in Formulation Development
From solving complex formulation challenges to delivering full product-development programs, outsourcing services organizations provide valuable expertise, experience, and technical know-how.
Advertisement
Articles in this issue
almost 22 years ago
An Overview of the Effect of Moisture on Compaction and Compressionalmost 22 years ago
The Pipeline Crisisalmost 22 years ago
Drug Safety and Access Top Policy Concerns for 2005almost 22 years ago
Comparison of EP "Heavy Metals" Test with USP "Conductivity" Testalmost 22 years ago
Patheon Places Big Bet with Mova Acquisitionalmost 22 years ago
January 2005almost 22 years ago
In the Spotlight-January 2005Advertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
Advertisement
Advertisement